Barclays’s Ingevity NGVT Stock Holding History

Barclays’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-192	Closed	-$9K	–	6751
2016 Q3	$9K	Sell	192 -448	-70%	-$18.9K	﹤0.01%	5833
2016 Q2	$22K	Buy	+640	New	+$20K	﹤0.01%	5228

Other funds holding NGVT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Barclays's NGVT Position: Q2 2026 in Review

Barclays reduced its Ingevity (NGVT) stake by 11% in Q2 2026, selling an estimated $74.7K and leaving 8,186 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #3103.

Barclays first reported a position in NGVT in Q2 2016 and has held it in 41 quarters since. The position peaked at $6.54M in Q3 2018. 315 funds tracked by Wall St. Rank hold NGVT as of Q2 2026.

Barclays held 8,186 shares of Ingevity worth $611K as of Q2 2026.
Barclays sold 1,038 Ingevity shares in Q2 2026, an estimated $74.7K.
Ingevity made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3103 holding.
Barclays first reported a position in Ingevity in Q2 2016 and has held it in 41 quarters since.
Barclays's Ingevity position peaked at $6.54M in Q3 2018.
315 funds tracked by Wall St. Rank held Ingevity as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.